首页> 外文期刊>Pulmonary pharmacology & therapeutics >Neutralization of both IL-1 alpha/IL-1 beta plays a major role in suppressing combined cigarette smoke/virus-induced pulmonary inflammation in mice
【24h】

Neutralization of both IL-1 alpha/IL-1 beta plays a major role in suppressing combined cigarette smoke/virus-induced pulmonary inflammation in mice

机译:IL-1α/ IL-1β的中和在抑制小鼠中抑制组合的香烟烟雾/病毒诱导的肺炎症方面发挥了重要作用

获取原文
获取原文并翻译 | 示例
       

摘要

Smoking is an important risk factor for the development of chronic obstructive pulmonary disease (COPD) and viral infections are believed to be major triggers of exacerbations, which periodically lead to a worsening of symptoms. The pro-inflammatory IL-1 family members IL-l alpha and IL-1 beta are increased in COPD patients and might contribute to disease pathology. We investigated whether individual or combined inhibition of these cytokines reduced lung inflammation in cigarette smoke (CS)-exposed and H1N1-infected BALB/c mice. Animals were treated with individual or combined antibodies (Abs) directed against IL-1 alpha, IL-1 beta or IL-1R1. Cells in BAL fluid and cytokines/chemokines in lung homogenate were determined. The viral load was, investigated. Blocking IL-1 alpha had significant suppressive effects on total cells, neutrophils, and macrophages. Furthermore, it reduced KC levels significantly. Blocking of IL-1 beta did not provide significant activity. In primary human bronchial epithelial air-liquid-interface cell cultures infected with H1N1, IL-l alpha Abs but not 1L-1 beta Abs reduced levels of TNF-alpha and IL-6. Concomitant usage of Abs against IL-1 alpha/IL-1 beta revealed strong effects in vivo and reduced total cells, neutrophils and macrophages. Additionally, levels of ICC, IL-6, TNF-alpha, MCP-1, M1P-1 alpha and MIP-1 beta were significantly reduced and ICAM-1 and MUC5 A/C mRNA expression was attenuated. The viral load decreased significantly upon combined IL-1 alpha/IL-1 beta Ab treatment. Blocking the IL-1R1 provided significant effects on total cells, neutrophils and macrophages but was inferior compared to inhibiting both its soluble ligands IL-1 alpha/IL-1 beta. Our results suggest that combined inhibition of IL-l alpha/IL-1 beta might be beneficial to reduce CS/H1N1-induced airway inflammation. Moreover, combined targeting of both IL-1 alpha-IL-1 beta might be more efficient compared to individual neutralization IL-l alpha or IL-1 beta or inhibition of the IL-1R1. (C) 2017 The Authors. Published by Elsevier Ltd.
机译:吸烟是慢性阻塞性肺病(COPD)的发展的重要危险因素,并且据信病毒感染是加剧的主要触发器,其定期导致症状恶化。 POPD患者的促炎IL-1家族成员IL-Lα和IL-1β增加,可能有助于病理学。我们研究了这些细胞因子的个体或结合抑制这些细胞因子是否降低了卷烟烟雾(CS)中的肺炎(CS) - 感染H1N1感染的BALB / C小鼠。用针对IL-1α,IL-1β或IL-1R1的个体或组合抗体(ABS)处理动物。确定了肺匀浆中BAL流体和细胞因子/趋化因子的细胞。研究了病毒载荷。阻断IL-1α对总细胞,中性粒细胞和巨噬细胞具有显着的抑制作用。此外,它显着降低了KC水平。阻断IL-1 Beta没有提供重大活动。在初级人支气管上皮空气 - 液体 - 界面细胞培养物中感染H1N1,IL-LαBAS,但不是1L-1βBSABS降低的TNF-α和IL-6。 ABS对IL-1α/ IL-1β的伴随使用揭示了体内强烈的效果,并减少了总细胞,中性粒细胞和巨噬细胞。另外,ICC,IL-6,TNF-α,MCP-1,M1P-1α和MIP-1β的水平显着降低,并且衰减了ICAM-1和MUC5 A / C mRNA表达。在IL-1α/ IL-1βBAB处理中,病毒载荷显着降低。阻断IL-1R1对总细胞,中性粒细胞和巨噬细胞的显着影响,但与抑制其可溶性配体IL-1α/ IL-1β相比,较差。我们的研究结果表明,IL-Lα/ IL-1β的合并抑制可能有利于降低Cs / H1N1诱导的气道炎症。此外,与单独的中和IL-Lα或IL-1β或IL-1R1的抑制相比,IL-1α-IL-1β的组合靶向可能更有效。 (c)2017作者。 elsevier有限公司出版

著录项

  • 来源
    《Pulmonary pharmacology & therapeutics》 |2017年第2017期|共10页
  • 作者单位

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immunol &

    Resp Dis Res Birkendorfer Str 65 Biberach;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immunol &

    Resp Dis Res Birkendorfer Str 65 Biberach;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immunol &

    Resp Dis Res Birkendorfer Str 65 Biberach;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immunol &

    Resp Dis Res Birkendorfer Str 65 Biberach;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immunol &

    Resp Dis Res Birkendorfer Str 65 Biberach;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immune Modulat &

    Biotherapeut Discovery Birkendorfer Str;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immune Modulat &

    Biotherapeut Discovery Birkendorfer Str;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immune Modulat &

    Biotherapeut Discovery Birkendorfer Str;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immunol &

    Resp Dis Res Birkendorfer Str 65 Biberach;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immune Modulat &

    Biotherapeut Discovery Birkendorfer Str;

    Boehringer Ingelheim Pharma GmbH &

    Co KG Immunol &

    Resp Dis Res Birkendorfer Str 65 Biberach;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 呼吸系及胸部疾病;
  • 关键词

    COPD; Pulmonary inflammation; Exacerbation; Virus; Treatment; IL-1 pathway;

    机译:COPD;肺炎;加剧;病毒;治疗;IL-1途径;
  • 入库时间 2022-08-20 06:46:13

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号